

Xpert® MRSA/SA SSTI

MRSA and *S. aureus* detection from skin and soft tissue infections in 62 minutes



The Need

- Surgical-site infections (SSIs) are a significant cause of **morbidity and mortality**¹
- ***S. aureus*** is one of the most common pathogens responsible for SSIs²
- **SSIs caused by MRSA** lead to worse clinical outcomes vs less resistant pathogens²
- The use of inappropriate initial antibiotic treatment can be associated with **adverse clinical outcomes and increased length of stay**³

The Solution

- The **Xpert MRSA/SA SSTI** test is a qualitative *in vitro* diagnostic test intended for the detection of *Staphylococcus aureus* (SA) and methicillin-resistant *Staphylococcus aureus* (MRSA) from skin and soft tissue infection swabs
- Laboratory efficiencies with **on-demand workflows** requiring minimal hands-on time
 - Optimized therapy to support improved patient outcomes and **reduced empirical prescribing**

The Impact

- Rapid detection enables more **targeted antibiotic selection**⁴
- **Improved patient management** with appropriate antimicrobial therapy⁵
- Significantly reduced **time to result** compared to culture methods⁵

1 Mengistu DA, Alemu A, Abdukadir AA, Mohammed Husen A, Ahmed F, Mohammed B, Musa I. Global Incidence of Surgical Site Infection Among Patients: Systematic Review and Meta-Analysis. Inquiry. 2023 Jan-Dec;60:469580231162549. doi: 10.1177/00469580231162549. PMID: 36964747; PMCID: PMC10041599.

2 Seidelman JL, Mantyh CR, Anderson DJ. Surgical Site Infection Prevention: A Review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

3 Nathwani D, et al. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int J Antimicrob Agents. 2016

4 May LS, et al. A Randomized Clinical Trial Comparing Use of Rapid Molecular Testing for Staphylococcus aureus for Patients With Cutaneous Abscesses in the Emergency Department With Standard of Care. Infect Control Hosp Epidemiol. 2015

5 Valour et al. (2014) Rapid detection of Staphylococcus aureus and methicillin resistance in bone and joint infection samples: evaluation of the GeneXpert MRSA/SA SSTI assay <https://www.sciencedirect.com/science/article/pii/S0732889313006391>



Xpert® MRSA/SA SSTI

Product Reference Sheet — US-IVD & CE-IVD

Test Reagent Kit	Xpert MRSA/SA SSTI	
Catalog Number	US-IVD: GXMRSA/SA-SSTI-10 CE-IVD: GXMRSA/SA-SSTI-CE	
Technology	Real-time RT-PCR	
Targets	<i>spa</i> , <i>mecA</i> , <i>SCCmec</i>	
Batch or On-Demand	On-demand	
Minimum Batch Size	1	
Sample Type	Skin or soft tissue infection site	
Sample Extraction	Automated/integrated	
Precision Pipetting	Not required	
TAT	In about an hour	
Hands-on Time	< 1 minute	
Sample Processing Controls (SPC)	✓	
Probe Check Control (PCC)	✓	
Positive Percent Agreement*	MRSA 93.8% (95% CI: 88.6–97.1)	SA+/MRSA 95.7% (95% CI: 92.2–97.9)
Negative Percent Agreement*	MRSA 97.3% (95% CI: 94.7–98.8)	SA+/MRSA 89.5% (95% CI: 84.6–93.3)
Sample Stability	2–8 °C for 5 days Room temperature for 24 hours	
Kit Storage	2–28 °C	
Commercial Controls	Refer to Package Insert or Contact Cepheid Technical Support	

* Xpert MRSA/SA SSTI compared to Reference Culture
IVD. *In Vitro* Diagnostic Medical Device. May not be available in all countries.

CORPORATE HEADQUARTERS

904 Caribbean Drive
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Solelh
81470 Maurens-Scopont France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAIL cepheid@cepheideurope.fr

www.Cepheid.com

© 2024 Cepheid. 5122-01

